v3.25.4
SUMMARY OF NUMBER OF OPTIONS GRANTED (Details) - Stock Option Plan [Member] - USD ($)
 6 Months Ended 12 Months Ended
Aug. 01, 2025
Jan. 31, 2026
Jul. 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Number of options, beginning balance 13,251 13,251  
Weighted average exercise price, beginning balance $ 896.61 $ 896.61  
Weighted average remaining contractual term (in years)   3 years 7 months 13 days 1 year 7 months 13 days
Aggregate intrinsic value, beginning balance  
Number of options, granted 37,700 37,700 [1]  
Weighted average exercise price, granted $ 12.50 $ 12.50 [1]  
Weighted average remaining contractual term (in years), granted [1]   4 years 9 months  
Aggregate intrinsic value, Granted [1]    
Number of options, ending balance   50,951 13,251
Weighted average exercise price, ending balance   $ 242.91 $ 896.61
Aggregate intrinsic value, ending balance  
Number of options, exercisable   22,676  
Weighted average exercise price, exercisable   $ 530.22  
Weighted average remaining contractual term (in years), exercisable   2 years 6 months 10 days  
Aggregate intrinsic value, exercisable    
[1] On August 1, 2025, the Company granted 37,700 stock options to employees and members of the scientific advisory board at an exercise price of $12.50 per share. All options vest quarterly over two years. The options expire on August 1, 2030. The grant-date fair value of the award was $218,784. The fair value of options granted during the six-month period ended January 31, 2026 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of 116%, expected term of 5.0 years, risk-free interest rate of 3.98%, dividend yield of 0%, and a stock price of $7.50 on the grant date.